Cargando…
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials
BACKGROUND: Interventional trials that evaluate treatment effects using surrogate endpoints have become increasingly common. This paper describes four linked empirical studies and the development of a framework for defining, interpreting and reporting surrogate endpoints in trials. METHODS: As part...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590868/ https://www.ncbi.nlm.nih.gov/pubmed/37877001 http://dx.doi.org/10.1016/j.eclinm.2023.102283 |
_version_ | 1785124092996747264 |
---|---|
author | Ciani, Oriana Manyara, Anthony M. Davies, Philippa Stewart, Derek Weir, Christopher J. Young, Amber E. Blazeby, Jane Butcher, Nancy J. Bujkiewicz, Sylwia Chan, An-Wen Dawoud, Dalia Offringa, Martin Ouwens, Mario Hróbjartssson, Asbjørn Amstutz, Alain Bertolaccini, Luca Bruno, Vito Domenico Devane, Declan Faria, Christina D.C.M. Gilbert, Peter B. Harris, Ray Lassere, Marissa Marinelli, Lucio Markham, Sarah Powers, John H. Rezaei, Yousef Richert, Laura Schwendicke, Falk Tereshchenko, Larisa G. Thoma, Achilles Turan, Alparslan Worrall, Andrew Christensen, Robin Collins, Gary S. Ross, Joseph S. Taylor, Rod S. |
author_facet | Ciani, Oriana Manyara, Anthony M. Davies, Philippa Stewart, Derek Weir, Christopher J. Young, Amber E. Blazeby, Jane Butcher, Nancy J. Bujkiewicz, Sylwia Chan, An-Wen Dawoud, Dalia Offringa, Martin Ouwens, Mario Hróbjartssson, Asbjørn Amstutz, Alain Bertolaccini, Luca Bruno, Vito Domenico Devane, Declan Faria, Christina D.C.M. Gilbert, Peter B. Harris, Ray Lassere, Marissa Marinelli, Lucio Markham, Sarah Powers, John H. Rezaei, Yousef Richert, Laura Schwendicke, Falk Tereshchenko, Larisa G. Thoma, Achilles Turan, Alparslan Worrall, Andrew Christensen, Robin Collins, Gary S. Ross, Joseph S. Taylor, Rod S. |
author_sort | Ciani, Oriana |
collection | PubMed |
description | BACKGROUND: Interventional trials that evaluate treatment effects using surrogate endpoints have become increasingly common. This paper describes four linked empirical studies and the development of a framework for defining, interpreting and reporting surrogate endpoints in trials. METHODS: As part of developing the CONSORT (Consolidated Standards of Reporting Trials) and SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) extensions for randomised trials reporting surrogate endpoints, we undertook a scoping review, e-Delphi study, consensus meeting, and a web survey to examine current definitions and stakeholder (including clinicians, trial investigators, patients and public partners, journal editors, and health technology experts) interpretations of surrogate endpoints as primary outcome measures in trials. FINDINGS: Current surrogate endpoint definitional frameworks are inconsistent and unclear. Surrogate endpoints are used in trials as a substitute of the treatment effects of an intervention on the target outcome(s) of ultimate interest, events measuring how patients feel, function, or survive. Traditionally the consideration of surrogate endpoints in trials has focused on biomarkers (e.g., HDL cholesterol, blood pressure, tumour response), especially in the medical product regulatory setting. Nevertheless, the concept of surrogacy in trials is potentially broader. Intermediate outcomes that include a measure of function or symptoms (e.g., angina frequency, exercise tolerance) can also be used as substitute for target outcomes (e.g., all-cause mortality)—thereby acting as surrogate endpoints. However, we found a lack of consensus among stakeholders on accepting and interpreting intermediate outcomes in trials as surrogate endpoints or target outcomes. In our assessment, patients and health technology assessment experts appeared more likely to consider intermediate outcomes to be surrogate endpoints than clinicians and regulators. INTERPRETATION: There is an urgent need for better understanding and reporting on the use of surrogate endpoints, especially in the setting of interventional trials. We provide a framework for the definition of surrogate endpoints (biomarkers and intermediate outcomes) and target outcomes in trials to improve future reporting and aid stakeholders' interpretation and use of trial surrogate endpoint evidence. FUNDING: SPIRIT-SURROGATE/CONSORT-SURROGATE project is Medical Research Council Better Research Better Health (MR/V038400/1) funded. |
format | Online Article Text |
id | pubmed-10590868 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-105908682023-10-24 A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials Ciani, Oriana Manyara, Anthony M. Davies, Philippa Stewart, Derek Weir, Christopher J. Young, Amber E. Blazeby, Jane Butcher, Nancy J. Bujkiewicz, Sylwia Chan, An-Wen Dawoud, Dalia Offringa, Martin Ouwens, Mario Hróbjartssson, Asbjørn Amstutz, Alain Bertolaccini, Luca Bruno, Vito Domenico Devane, Declan Faria, Christina D.C.M. Gilbert, Peter B. Harris, Ray Lassere, Marissa Marinelli, Lucio Markham, Sarah Powers, John H. Rezaei, Yousef Richert, Laura Schwendicke, Falk Tereshchenko, Larisa G. Thoma, Achilles Turan, Alparslan Worrall, Andrew Christensen, Robin Collins, Gary S. Ross, Joseph S. Taylor, Rod S. eClinicalMedicine Articles BACKGROUND: Interventional trials that evaluate treatment effects using surrogate endpoints have become increasingly common. This paper describes four linked empirical studies and the development of a framework for defining, interpreting and reporting surrogate endpoints in trials. METHODS: As part of developing the CONSORT (Consolidated Standards of Reporting Trials) and SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) extensions for randomised trials reporting surrogate endpoints, we undertook a scoping review, e-Delphi study, consensus meeting, and a web survey to examine current definitions and stakeholder (including clinicians, trial investigators, patients and public partners, journal editors, and health technology experts) interpretations of surrogate endpoints as primary outcome measures in trials. FINDINGS: Current surrogate endpoint definitional frameworks are inconsistent and unclear. Surrogate endpoints are used in trials as a substitute of the treatment effects of an intervention on the target outcome(s) of ultimate interest, events measuring how patients feel, function, or survive. Traditionally the consideration of surrogate endpoints in trials has focused on biomarkers (e.g., HDL cholesterol, blood pressure, tumour response), especially in the medical product regulatory setting. Nevertheless, the concept of surrogacy in trials is potentially broader. Intermediate outcomes that include a measure of function or symptoms (e.g., angina frequency, exercise tolerance) can also be used as substitute for target outcomes (e.g., all-cause mortality)—thereby acting as surrogate endpoints. However, we found a lack of consensus among stakeholders on accepting and interpreting intermediate outcomes in trials as surrogate endpoints or target outcomes. In our assessment, patients and health technology assessment experts appeared more likely to consider intermediate outcomes to be surrogate endpoints than clinicians and regulators. INTERPRETATION: There is an urgent need for better understanding and reporting on the use of surrogate endpoints, especially in the setting of interventional trials. We provide a framework for the definition of surrogate endpoints (biomarkers and intermediate outcomes) and target outcomes in trials to improve future reporting and aid stakeholders' interpretation and use of trial surrogate endpoint evidence. FUNDING: SPIRIT-SURROGATE/CONSORT-SURROGATE project is Medical Research Council Better Research Better Health (MR/V038400/1) funded. Elsevier 2023-10-17 /pmc/articles/PMC10590868/ /pubmed/37877001 http://dx.doi.org/10.1016/j.eclinm.2023.102283 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Articles Ciani, Oriana Manyara, Anthony M. Davies, Philippa Stewart, Derek Weir, Christopher J. Young, Amber E. Blazeby, Jane Butcher, Nancy J. Bujkiewicz, Sylwia Chan, An-Wen Dawoud, Dalia Offringa, Martin Ouwens, Mario Hróbjartssson, Asbjørn Amstutz, Alain Bertolaccini, Luca Bruno, Vito Domenico Devane, Declan Faria, Christina D.C.M. Gilbert, Peter B. Harris, Ray Lassere, Marissa Marinelli, Lucio Markham, Sarah Powers, John H. Rezaei, Yousef Richert, Laura Schwendicke, Falk Tereshchenko, Larisa G. Thoma, Achilles Turan, Alparslan Worrall, Andrew Christensen, Robin Collins, Gary S. Ross, Joseph S. Taylor, Rod S. A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials |
title | A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials |
title_full | A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials |
title_fullStr | A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials |
title_full_unstemmed | A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials |
title_short | A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials |
title_sort | framework for the definition and interpretation of the use of surrogate endpoints in interventional trials |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590868/ https://www.ncbi.nlm.nih.gov/pubmed/37877001 http://dx.doi.org/10.1016/j.eclinm.2023.102283 |
work_keys_str_mv | AT cianioriana aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT manyaraanthonym aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT daviesphilippa aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT stewartderek aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT weirchristopherj aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT youngambere aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT blazebyjane aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT butchernancyj aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT bujkiewiczsylwia aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT chananwen aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT dawouddalia aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT offringamartin aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT ouwensmario aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT hrobjartsssonasbjørn aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT amstutzalain aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT bertolacciniluca aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT brunovitodomenico aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT devanedeclan aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT fariachristinadcm aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT gilbertpeterb aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT harrisray aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT lasseremarissa aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT marinellilucio aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT markhamsarah aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT powersjohnh aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT rezaeiyousef aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT richertlaura aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT schwendickefalk aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT tereshchenkolarisag aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT thomaachilles aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT turanalparslan aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT worrallandrew aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT christensenrobin aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT collinsgarys aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT rossjosephs aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT taylorrods aframeworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT cianioriana frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT manyaraanthonym frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT daviesphilippa frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT stewartderek frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT weirchristopherj frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT youngambere frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT blazebyjane frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT butchernancyj frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT bujkiewiczsylwia frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT chananwen frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT dawouddalia frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT offringamartin frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT ouwensmario frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT hrobjartsssonasbjørn frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT amstutzalain frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT bertolacciniluca frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT brunovitodomenico frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT devanedeclan frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT fariachristinadcm frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT gilbertpeterb frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT harrisray frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT lasseremarissa frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT marinellilucio frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT markhamsarah frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT powersjohnh frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT rezaeiyousef frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT richertlaura frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT schwendickefalk frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT tereshchenkolarisag frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT thomaachilles frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT turanalparslan frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT worrallandrew frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT christensenrobin frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT collinsgarys frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT rossjosephs frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials AT taylorrods frameworkforthedefinitionandinterpretationoftheuseofsurrogateendpointsininterventionaltrials |